Hanmi Pharm. Co., Ltd. (128940.KS)
KRW 269500.0
(-1.46%)
KRW 269500.0
(-1.46%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 610.97 Billion KRW | 9.01% |
| 2022 | 560.46 Billion KRW | 10.47% |
| 2021 | 507.33 Billion KRW | -4.63% |
| 2020 | 531.94 Billion KRW | 0.63% |
| 2019 | 528.6 Billion KRW | 15.58% |
| 2018 | 457.34 Billion KRW | 4.84% |
| 2017 | 436.24 Billion KRW | 0.5% |
| 2016 | 434.08 Billion KRW | -38.64% |
| 2015 | 707.48 Billion KRW | 82.32% |
| 2014 | 388.05 Billion KRW | 9.45% |
| 2013 | 354.55 Billion KRW | 2.32% |
| 2012 | 346.53 Billion KRW | 11.76% |
| 2011 | 310.05 Billion KRW | 55.94% |
| 2010 | 198.83 Billion KRW | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 148.57 Billion KRW | -0.85% |
| 2024 Q3 | 311.1 Billion KRW | -0.62% |
| 2024 Q1 | 149.84 Billion KRW | -12.25% |
| 2023 Q2 | -147.02 Billion KRW | -199.92% |
| 2023 Q3 | -141.33 Billion KRW | 3.87% |
| 2023 Q4 | 170.76 Billion KRW | 220.82% |
| 2023 FY | 610.97 Billion KRW | 9.01% |
| 2023 Q1 | 147.14 Billion KRW | -3.48% |
| 2022 FY | 560.46 Billion KRW | 10.47% |
| 2022 Q4 | 152.45 Billion KRW | 7.56% |
| 2022 Q3 | 141.74 Billion KRW | 5.48% |
| 2022 Q1 | 131.88 Billion KRW | -7.13% |
| 2022 Q2 | 134.38 Billion KRW | 1.9% |
| 2021 Q2 | 125.54 Billion KRW | 7.94% |
| 2021 Q1 | 116.3 Billion KRW | -1.97% |
| 2021 Q4 | 142 Billion KRW | 15.0% |
| 2021 Q3 | 123.47 Billion KRW | -1.65% |
| 2021 FY | 507.33 Billion KRW | -4.63% |
| 2020 Q2 | 119.14 Billion KRW | -12.04% |
| 2020 Q3 | 158.68 Billion KRW | 33.18% |
| 2020 Q4 | 118.64 Billion KRW | -25.23% |
| 2020 FY | 531.94 Billion KRW | 0.63% |
| 2020 Q1 | 135.45 Billion KRW | -4.23% |
| 2019 Q2 | 121.52 Billion KRW | -10.96% |
| 2019 Q4 | 141.44 Billion KRW | 9.52% |
| 2019 FY | 528.6 Billion KRW | 15.58% |
| 2019 Q1 | 136.47 Billion KRW | 11.87% |
| 2019 Q3 | 129.15 Billion KRW | 6.28% |
| 2018 Q2 | 113.44 Billion KRW | -1.89% |
| 2018 FY | 457.34 Billion KRW | 4.84% |
| 2018 Q4 | 121.99 Billion KRW | 14.8% |
| 2018 Q3 | 106.27 Billion KRW | -6.32% |
| 2018 Q1 | 115.62 Billion KRW | -5.14% |
| 2017 Q4 | 121.88 Billion KRW | 13.55% |
| 2017 FY | 436.24 Billion KRW | 0.5% |
| 2017 Q2 | 103.98 Billion KRW | 0.93% |
| 2017 Q1 | 103.02 Billion KRW | 23.11% |
| 2017 Q3 | 107.34 Billion KRW | 3.23% |
| 2016 FY | 434.08 Billion KRW | -38.64% |
| 2016 Q1 | 121.24 Billion KRW | -61.22% |
| 2016 Q2 | 119.87 Billion KRW | -1.13% |
| 2016 Q4 | 83.69 Billion KRW | -23.41% |
| 2016 Q3 | 109.27 Billion KRW | -8.84% |
| 2015 Q2 | 144.33 Billion KRW | 26.11% |
| 2015 FY | 707.48 Billion KRW | 82.32% |
| 2015 Q1 | 114.44 Billion KRW | 0.61% |
| 2015 Q4 | 312.66 Billion KRW | 129.83% |
| 2015 Q3 | 136.03 Billion KRW | -5.75% |
| 2014 Q1 | 86.37 Billion KRW | -9.99% |
| 2014 Q4 | 113.75 Billion KRW | 19.76% |
| 2014 Q3 | 94.98 Billion KRW | 2.21% |
| 2014 FY | 388.05 Billion KRW | 9.45% |
| 2014 Q2 | 92.93 Billion KRW | 7.59% |
| 2013 Q4 | 95.96 Billion KRW | 5.79% |
| 2013 Q1 | 78.05 Billion KRW | -9.57% |
| 2013 Q3 | 90.71 Billion KRW | 0.97% |
| 2013 Q2 | 89.83 Billion KRW | 15.1% |
| 2013 FY | 354.55 Billion KRW | 2.32% |
| 2012 Q4 | 86.31 Billion KRW | 2.63% |
| 2012 FY | 346.53 Billion KRW | 11.76% |
| 2012 Q2 | 96.4 Billion KRW | 20.94% |
| 2012 Q1 | 79.71 Billion KRW | 0.0% |
| 2012 Q3 | 84.1 Billion KRW | -12.76% |
| 2011 Q3 | 61.35 Billion KRW | 2.71% |
| 2011 Q1 | 57.36 Billion KRW | 0.0% |
| 2011 FY | 310.05 Billion KRW | 55.94% |
| 2011 Q2 | 59.73 Billion KRW | 4.14% |
| 2011 Q4 | - KRW | -100.0% |
| 2010 FY | 198.83 Billion KRW | 0.0% |
| 2010 Q3 | 87.97 Billion KRW | 0.0% |
| 2010 Q4 | - KRW | -100.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -1192.951% |
| Dong-A Socio Holdings Co., Ltd. | 297.99 Billion KRW | -105.029% |
| Ildong Holdings Co., Ltd. | 278.43 Billion KRW | -119.427% |
| HANDOK Inc. | 153.76 Billion KRW | -297.331% |
| Kukje Pharma Co., Ltd. | 69.21 Billion KRW | -782.731% |
| Yuhan Corporation | 489.94 Billion KRW | -24.702% |
| Dong-A ST Co., Ltd. | 306.95 Billion KRW | -99.04% |
| SAMSUNG PHARM. Co., LTD. | 41.78 Billion KRW | -1362.018% |
| Hanall Biopharma Co.,Ltd | 71.98 Billion KRW | -748.766% |
| Ilyang Pharmaceutical Co.,Ltd | 174.14 Billion KRW | -250.833% |
| Dong Sung Bio Pharm.Co.,Ltd. | 40.05 Billion KRW | -1425.399% |
| MYUNGMOON Pharm co.,Ltd | 93.55 Billion KRW | -553.084% |
| Hana Pharm Co., Ltd. | 114.72 Billion KRW | -432.552% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -1192.951% |
| Ilsung Pharmaceuticals Co., Ltd. | 42.47 Billion KRW | -1338.533% |
| REYON Pharmaceutical Co., Ltd. | 75.04 Billion KRW | -714.093% |
| Aprogen pharmaceuticals,Inc. | 58.64 Billion KRW | -941.824% |
| JW Holdings Corporation | 301.25 Billion KRW | -102.807% |
| Ildong Pharmaceutical Co., Ltd. | 260.95 Billion KRW | -134.128% |
| Chong Kun Dang Pharmaceutical Corp. | 408.65 Billion KRW | -49.507% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | -155.732% |
| Shin Poong Pharm.Co.,Ltd. | 127.66 Billion KRW | -378.556% |
| Hyundai Pharmaceutical Co., Ltd. | 68.31 Billion KRW | -794.395% |
| Samil Pharmaceutical Co.,Ltd | 65.75 Billion KRW | -829.212% |
| Jeil Pharmaceutical Co.,Ltd | 174.92 Billion KRW | -249.273% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -1192.951% |
| Kwang Dong Pharmaceutical Co., Ltd. | 249.12 Billion KRW | -145.249% |
| Daewoong pharmaceutical Co.,Ltd | 560.43 Billion KRW | -9.018% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | -155.732% |
| Yuhan Corporation | 489.94 Billion KRW | -24.702% |
| Jeil Pharma Holdings Inc | 193.66 Billion KRW | -215.48% |
| Yungjin Pharm. Co., Ltd. | 69.46 Billion KRW | -779.491% |
| Suheung Co., Ltd. | 56.03 Billion KRW | -990.394% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | -155.732% |
| Samjin Pharmaceuticals Co., Ltd. | 126.39 Billion KRW | -383.39% |
| Korea United Pharm Inc. | 118.21 Billion KRW | -416.834% |
| CKD Bio Corp. | 25.19 Billion KRW | -2324.893% |
| Daewon Pharmaceutical Co., Ltd. | 221.99 Billion KRW | -175.213% |
| Dongwha Pharm.Co.,Ltd | 165.11 Billion KRW | -270.031% |
| Whan In Pharm Co.,Ltd. | 66.41 Billion KRW | -819.895% |
| Shin Poong Pharm.Co.,Ltd. | 127.66 Billion KRW | -378.556% |
| Chong Kun Dang Holdings Corp. | 350.71 Billion KRW | -74.206% |
| Boryung Corporation | 285.16 Billion KRW | -114.254% |
| Bukwang Pharmaceutical Co., Ltd. | 87.54 Billion KRW | -597.916% |
| Ilyang Pharmaceutical Co.,Ltd | 174.14 Billion KRW | -250.833% |
| JW Lifescience Corporation | 20.26 Billion KRW | -2915.413% |